EIF2A and lung carcinoma: To this end we treated A549 lung carcinoma, HT1080 fibrosarcoma and HepG2 hepatocarcinoma cells with this drug and observed an increase in the levels of phosphorylated eIF2α at all time points examined (Figure 1A).